| Bioactivity | PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC50 of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy[1]. |
| Invitro | PARP7-IN-22 (XLY-1) (5μM - 20μM, 14天) 对 CT26 细胞的活性没有显著影响[1]。PARP7-IN-22 (XLY-1) (49 nM - 4000 nM, 72小时) 以剂量依赖性方式显著增强了 IFN-β 和 CXCL10 的表达以及 STAT1 的磷酸化[1]。PARP7-IN-22 (XLY-1) (49 nM - 4000 nM, 72 小时) 处理显著增加了蛋白激酶 TBK 1的磷酸化[1]。PARP7-IN-22 (XLY-1) (49 nM - 4000 nM, 72 小时) 有效地促进了 I 型干扰素信号传导级联反应，从而发挥了抗肿瘤作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PARP7-IN-22 相关抗体: RT-PCR[1] Cell Line: |
| In Vivo | PARP7-IN-22 (XLY-1) (雄性大鼠，5 mg/kg，静脉注射；30 mg/kg，口服；0.5-24 小时) 可用于进一步的体内药效学研究[1]。PARP7-IN-22 (CT26 同种移植模型，25 或 50 mg/kg，口服，14 天) 在 CT26 同种移植模型中展示出优异的抗肿瘤增殖效果[1]。PARP7-IN-22 (CT26 同种移植模型，50 mg/kg，口服，14 天) 促进T 细胞浸润肿瘤组织，并表现出靶向效应[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C19H22F6N8O2 |
| Molar Mass | 508.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang J, et al. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy[J]. Bioorganic Chemistry, 2024, 148: 107469. |